The applying from Lykos — a drug business incubated through the Multidisciplinary Association for Psychedelic Studies, or MAPS — arrived on the FDA under a cloud of controversy. Former trial individuals experienced alleged adverse activities weren't claimed — including feelings of suicidality following the treatment — and that bias amid tho